Editas Medicine (EDIT) Net Income towards Common Stockholders (QoQ) (2015 - 2025)
Editas Medicine (EDIT) Net Income towards Common Stockholders (QoQ) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Editas Medicine | 242.79 Mn | 96.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 41.75% |
| Jun 30, 2025 | 34.10% |
| Mar 31, 2025 | -35.58% |
| Dec 31, 2024 | 6.40% |
| Sep 30, 2024 | 8.09% |
| Jun 30, 2024 | -2.74% |
| Mar 31, 2024 | -222.18% |
| Dec 31, 2023 | 84.62% |
| Sep 30, 2023 | 73.78% |
| Jun 30, 2023 | -78.37% |
| Mar 31, 2023 | -390.72% |
| Dec 31, 2022 | 96.36% |
| Sep 30, 2022 | -43.29% |
| Jun 30, 2022 | 72.29% |
| Mar 31, 2022 | -11,778.43% |
| Dec 31, 2021 | 50.05% |
| Sep 30, 2021 | 48.34% |
| Jun 30, 2021 | -30.54% |
| Mar 31, 2021 | -60.16% |
| Dec 31, 2020 | -899.32% |